Events

CERIS workshop: Foresight and Key Enabling Technologies
MAR
Tue
05
09:00 - 19:00

This was 1 year ago

Location

Brussels

Le Bouche à Oreille
Rue Félix Hap 11
1040 Etterbeek
Brussels, Belgium
Programmes
Security

The Community for European Research and Innovation for Security (CERIS) is organising a workshop on foresight and key enabling technologies on 5 March 2024 in Brussels.

The workshop will focus on anticipating threats and opportunities in the context of new emerging technologies, including the use of these technologies in a given policy, operational, industrial and societal context.

During this event, key components will be analysed that play a role in the foresight approach to civil security, in the context of Key Enabling Technologies (KETs).

The agenda will be shared at a later stage. Registration is free, but mandatory. You can find more information on the official website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.